ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

PURPOSE: Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non–small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Shaw, Alice T., Solomon, Benjamin J., Besse, Benjamin, Bauer, Todd M., Lin, Chia-Chi, Soo, Ross A., Riely, Gregory J., Ou, Sai-Hong Ignatius, Clancy, Jill S., Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D. Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M., Felip, Enriqueta, Martini, Jean-François
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2019
Schlagworte:
RAPID COMMUNICATION
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6544460/
https://ncbi.nlm.nih.gov/pubmed/30892989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02236
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge